The Secretary of State for Health

Oxford University Innovation Limited

Micropharm Limited

Miles Carroll

Ann Williams

Yper Hall

John Landon

David Stuart

Stuart Dowall

Roger Hewson

Thomas Bowden

Karen Buttigieg

Stephen Findlay-Wilson

Aleksandra Miloszewska

Ian Cameron

Antra Zeltina

The present invention provides antibodies, for use in the treatment, suppression prevention of Filovirus disease, particularly Ebola virus disease. Also provided immunogens for use in eliciting such antibodies.

Filovirus therapy

There is provided an antigenic composition comprising (a) a first mycobacterial antigenic polypeptide or a first mycobacterial polynucleotide; and (b) a second mycobacterial antigenic polypeptide or a second mycobacterial polynucleotide; wherein: (i) said first mycobacterial antigenic polypeptide comprises a polypeptide sequence having at least 70% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 1 or 7, or a fragment thereof having at least 7 consecutive amino acids thereof; (ii) said first mycobacterial polynucleotide comprises a polynucleotide sequence encoding said first mycobacterial antigenic polypeptide; (iii) said second mycobacterial antigenic polypeptide comprises a polypeptide sequence having at least 70% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 5, or a fragment thereof having at least 7 consecutive amino acids thereof; and (iv) said second mycobacterial polynucleotide comprises a polynucleotide sequence encoding said second mycobacterial polypeptide.

Mycobacterial antigen composition

Growing community of inventors

Salisbury, United Kingdom

Miles Carroll